 |
Cabaletta Bio
Last updated: October 12, 2024
Founders: Aimee Payne, Michael Milone, Steven Nichtberger
USA | Funding: $210M (+)
Website: https://www.cabalettabio.com/
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Website: https://www.cabalettabio.com/
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
